1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY EXCIPIENT
4.3.2 MARKET SEGMENTATION BY BIOLOGICS
4.3.3 MARKET SEGMENTATION BY SCALE OF OPERATION
4.3.4 MARKET SEGMENTATION BY END-USER
4.3.5 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION

6 MARKET AT A GLANCE

7 INTRODUCTION
7.1 OVERVIEW
7.2 MARKET SYNOPSIS
7.2.1 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SCENARIO
7.2.2 BIOLOGICS - PIPELINE AND PRODUCT APPROVALS, A MAJOR DRIVER FOR BIOPHARMACEUTICAL EXCIPIENTS
7.2.3 NOVEL EXCIPIENTS CREATING A MAJOR SHIFT FROM TRADITIONAL EXCIPIENTS
7.2.4 GROWING TREND OF OUTSOURCING THE MANUFACTURE OF BIOPHARMACEUTICAL EXCIPIENTS
7.2.5 CHALLENGES RESTRAINING THE GROWTH OF BIOPHARMACEUTICAL EXCIPIENTS
7.2.6 IMPACT OF COVID-19 ON BIOPHARMACEUTICAL EXCIPIENTS
7.2.7 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS: MARKET SEGMENTATIONS
7.2.8 COMPETITIVE LANDSCAPE

8 MARKET OPPORTUNITIES & TRENDS
8.1 EMERGING DEMAND FOR NOVEL EXCIPIENTS IN DRUG PRODUCT DEVELOPMENT
8.2 HIGH DEMAND FOR VACCINES AND CELL & GENE THERAPY-BASED EXCIPIENTS
8.3 EXHAUSTIVE PIPELINE OF BIOLOGICS & BIOSIMILARS
8.4 GROWING PENETRATION OF BIOPHARMACEUTICAL DRUGS

9 MARKET GROWTH ENABLERS
9.1 GROWING PREVALENCE OF CANCER AND INFECTIOUS DISEASES
9.2 RISING NUMBER OF PRODUCT APPROVALS FOR BIOLOGICS
9.3 INCREASING NEED FOR OUTSOURCING BIOPHARMACEUTICAL EXCIPIENT MANUFACTURING
9.4 EMERGING NEED FOR MULTI-FUNCTIONAL EXCIPIENTS

10 MARKET RESTRAINTS
10.1 REGULATORY CHALLENGES IN MANUFACTURING BIOPHARMACEUTICAL EXCIPIENTS
10.2 SUPPLY CHAIN AND INTEGRITY ISSUES WITH BIOPHARMACEUTICAL EXCIPIENTS
10.3 CHALLENGES OF FORMULATING BIOPHARMACEUTICAL EXCIPIENTS

11 MARKET LANDSCAPE
11.1 MARKET OVERVIEW
11.2 MARKET SIZE & FORECAST
11.2.1 INSIGHTS BY EXCIPIENT
11.2.2 INSIGHTS BY BIOLOGICS
11.2.3 INSIGHTS BY SCALE OF OPERATION
11.2.4 INSIGHTS BY END-USERS
11.2.5 INSIGHTS BY GEOGRAPHY
11.2.6 IMPACT OF COVID-19
11.3 FIVE FORCES ANALYSIS
11.3.1 THREAT OF NEW ENTRANTS
11.3.2 BARGAINING POWER OF SUPPLIERS
11.3.3 BARGAINING POWER OF BUYERS
11.3.4 THREAT OF SUBSTITUTES
11.3.5 COMPETITIVE RIVALRY

12 EXCIPIENT
12.1 MARKET SNAPSHOT & GROWTH ENGINE
12.2 MARKET OVERVIEW
12.3 BULKING AGENTS
12.3.1 MARKET OVERVIEW
12.3.2 MARKET SIZE & FORECAST
12.3.3 BULKING AGENTS: GEOGRAPHY SEGMENTATION
12.4 SOLUBILIZERS & SURFACTANTS
12.4.1 MARKET OVERVIEW
12.4.2 MARKET SIZE & FORECAST
12.4.3 SOLUBILIZERS & SURFACTANTS: GEOGRAPHY SEGMENTATION
12.5 BUFFERING & TONICITY AGENTS
12.5.1 MARKET OVERVIEW
12.5.2 MARKET SIZE & FORECAST
12.5.3 BUFFERING & TONICITY AGENTS: GEOGRAPHY SEGMENTATION
12.6 OTHERS
12.6.1 MARKET OVERVIEW
12.6.2 MARKET SIZE & FORECAST
12.6.3 OTHERS: GEOGRAPHY SEGMENTATION

13 BIOLOGICS
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 MONOCLONAL ANTIBODIES
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.3.3 MONOCLONAL ANTIBODIES: GEOGRAPHY SEGMENTATION
13.4 VACCINES
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.4.3 VACCINES: GEOGRAPHY SEGMENTATION
13.5 OTHERS
13.5.1 MARKET OVERVIEW
13.5.2 MARKET SIZE & FORECAST
13.5.3 OTHERS: GEOGRAPHY SEGMENTATION

14 SCALE OF OPERATION
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 COMMERCIAL
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.3.3 COMMERCIAL: GEOGRAPHY SEGMENTATION
14.4 RESEARCH
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.4.3 RESEARCH: GEOGRAPHY SEGMENTATION

15 END-USER
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 PHARMA & BIOTECH COMPANIES
15.3.1 MARKET OVERVIEW
15.3.2 MARKET SIZE & FORECAST
15.3.3 PHARMA & BIOTECH COMPANIES: GEOGRAPHY SEGMENTATION
15.4 CMOS & CDMOS
15.4.1 MARKET OVERVIEW
15.4.2 MARKET SIZE & FORECAST
15.4.3 CMOS & CDMOS: GEOGRAPHY SEGMENTATION
15.5 ACADEMIC & RESEARCH INSTITUTES
15.5.1 MARKET OVERVIEW
15.5.2 MARKET SIZE & FORECAST
15.5.3 ACADEMIC & RESEARCH INSTITUTES: GEOGRAPHY SEGMENTATION

16 GEOGRAPHY
16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 GEOGRAPHIC OVERVIEW

17 NORTH AMERICA
17.1 MARKET OVERVIEW
17.2 MARKET SIZE & FORECAST
17.2.1 NORTH AMERICA: EXCIPIENT
17.2.2 NORTH AMERICA: BIOLOGICS
17.2.3 NORTH AMERICA: SCALE OF OPERATION
17.2.4 NORTH AMERICA: END-USER
17.3 KEY COUNTRIES
17.3.1 US: MARKET SIZE & FORECAST
17.3.2 CANADA: MARKET SIZE & FORECAST

18 EUROPE
18.1 MARKET OVERVIEW
18.2 MARKET SIZE & FORECAST
18.2.1 EUROPE: EXCIPIENT
18.2.2 EUROPE: BIOLOGICS
18.2.3 EUROPE: SCALE OF OPERATION
18.2.4 EUROPE: END-USER
18.3 KEY COUNTRIES
18.3.1 GERMANY: MARKET SIZE & FORECAST
18.3.2 FRANCE: MARKET SIZE & FORECAST
18.3.3 UK: MARKET SIZE & FORECAST
18.3.4 SWITZERLAND: MARKET SIZE & FORECAST
18.3.5 ITALY: MARKET SIZE & FORECAST
18.3.6 SPAIN: MARKET SIZE & FORECAST

19 APAC
19.1 MARKET OVERVIEW
19.2 MARKET SIZE & FORECAST
19.2.1 APAC: EXCIPIENT
19.2.2 APAC: BIOLOGICS
19.2.3 APAC: SCALE OF OPERATION
19.2.4 APAC: END-USER
19.3 KEY COUNTRIES
19.3.1 CHINA: MARKET SIZE & FORECAST
19.3.2 JAPAN: MARKET SIZE & FORECAST
19.3.3 SOUTH KOREA: MARKET SIZE & FORECAST
19.3.4 INDIA: MARKET SIZE & FORECAST
19.3.5 AUSTRALIA: MARKET SIZE & FORECAST

20 LATIN AMERICA
20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORECAST
20.2.1 LATIN AMERICA: EXCIPIENT
20.2.2 LATIN AMERICA: BIOLOGICS
20.2.3 LATIN AMERICA: SCALE OF OPERATION
20.2.4 LATIN AMERICA: END-USER
20.3 KEY COUNTRIES
20.3.1 BRAZIL: MARKET SIZE & FORECAST
20.3.2 MEXICO: MARKET SIZE & FORECAST
20.3.3 ARGENTINA: MARKET SIZE & FORECAST

21 MIDDLE EAST & AFRICA
21.1 MARKET OVERVIEW
21.2 MARKET SIZE & FORECAST
21.2.1 MIDDLE EAST & AFRICA: EXCIPIENT
21.2.2 MIDDLE EAST & AFRICA: BIOLOGICS
21.2.3 MIDDLE EAST & AFRICA: SCALE OF OPERATION
21.2.4 MIDDLE EAST & AFRICA: END-USER
21.3 KEY COUNTRIES
21.3.1 TURKEY: MARKET SIZE & FORECAST
21.3.2 SAUDI ARABIA: MARKET SIZE & FORECAST
21.3.3 UAE: MARKET SIZE & FORECAST
21.3.4 SOUTH AFRICA: MARKET SIZE & FORECAST

22 COMPETITIVE LANDSCAPE
22.1 COMPETITION OVERVIEW
22.2 MARKET SHARE ANALYSIS
22.2.1 MERCK KGAA
22.2.2 BASF SE
22.2.3 AVANTOR
22.2.4 EVONIK INDUSTRIES
22.2.5 ROQUETTE FRÈRES
22.2.6 ASSOCIATED BRITISH FOODS

23 KEY COMPANY PROFILES
23.1 MERCK KGAA
23.1.1 BUSINESS OVERVIEW
23.1.2 PRODUCT OFFERINGS
23.1.3 KEY STRATEGIES
23.1.4 KEY STRENGTHS
23.1.5 KEY OPPORTUNITIES
23.2 BASF SE
23.2.1 BUSINESS OVERVIEW
23.2.2 PRODUCT OFFERINGS
23.2.3 KEY STRATEGIES
23.2.4 KEY STRENGTHS
23.2.5 KEY OPPORTUNITIES
23.3 AVANTOR
23.3.1 BUSINESS OVERVIEW
23.3.2 PRODUCT OFFERINGS
23.3.3 KEY STRATEGIES
23.3.4 KEY STRENGTHS
23.3.5 KEY OPPORTUNITIES
23.4 EVONIK INDUSTRIES
23.4.1 BUSINESS OVERVIEW
23.4.2 PRODUCT OFFERINGS
23.4.3 KEY STRATEGIES
23.4.4 KEY STRENGTHS
23.4.5 KEY OPPORTUNITIES
23.5 ROQUETTE FRÈRES
23.5.1 BUSINESS OVERVIEW
23.5.2 PRODUCT OFFERINGS
23.5.3 KEY STRATEGIES
23.5.4 KEY STRENGTHS
23.5.5 KEY OPPORTUNITIES
23.6 ASSOCIATED BRITISH FOODS
23.6.1 BUSINESS OVERVIEW
23.6.2 PRODUCT OFFERINGS
23.6.3 KEY STRATEGIES
23.6.4 KEY STRENGTHS
23.6.5 KEY OPPORTUNITIES

24 OTHER PROMINENT VENDORS
24.1 ACETO
24.1.1 BUSINESS OVERVIEW
24.1.2 PRODUCT OFFERINGS
24.2 ANGUS CHEMICAL COMPANY
24.2.1 BUSINESS OVERVIEW
24.2.2 PRODUCT OFFERINGS
24.3 APOTHECON PHARMACEUTICALS
24.3.1 BUSINESS OVERVIEW
24.3.2 PRODUCT OFFERINGS
24.4 ASHLAND
24.4.1 BUSINESS OVERVIEW
24.4.2 PRODUCT OFFERINGS
24.5 BIOSPECTRA
24.5.1 BUSINESS OVERVIEW
24.5.2 PRODUCT OFFERINGS
24.6 BOC SCIENCES
24.6.1 BUSINESS OVERVIEW
24.6.2 PRODUCT OFFERINGS
24.7 CG GROUP
24.7.1 BUSINESS OVERVIEW
24.7.2 PRODUCT OFFERINGS
24.8 CLARIANT
24.8.1 BUSINESS OVERVIEW
24.8.2 PRODUCT OFFERINGS
24.9 COLORCON
24.9.1 BUSINESS OVERVIEW
24.9.2 PRODUCT OFFERINGS
24.10 DFE PHARMA
24.10.1 BUSINESS OVERVIEW
24.10.2 PRODUCT OFFERINGS
24.11 DOW
24.11.1 BUSINESS OVERVIEW
24.11.2 PRODUCT OFFERINGS
24.12 EASTMAN CHEMICAL COMPANY
24.12.1 BUSINESS OVERVIEW
24.12.2 PRODUCT OFFERINGS
24.13 IMCD
24.13.1 BUSINESS OVERVIEW
24.13.2 PRODUCT OFFERINGS
24.14 INNOPHOS
24.14.1 BUSINESS OVERVIEW
24.14.2 PRODUCT OFFERINGS
24.15 INVITRIA
24.15.1 BUSINESS OVERVIEW
24.15.2 PRODUCT OFFERINGS
24.16 JRS PHARMA
24.16.1 BUSINESS OVERVIEW
24.16.2 PRODUCT OFFERINGS
24.17 KIRSCH PHARMA
24.17.1 BUSINESS OVERVIEW
24.17.2 PRODUCT OFFERINGS
24.18 MEGGLE
24.18.1 BUSINESS OVERVIEW
24.18.2 PRODUCT OFFERINGS
24.19 NOVO NORDISK
24.19.1 BUSINESS OVERVIEW
24.19.2 PRODUCT OFFERINGS
24.20 PFANSTIEHL
24.20.1 BUSINESS OVERVIEW
24.20.2 PRODUCT OFFERINGS
24.21 PHARMONIX BIOLOGICALS
24.21.1 BUSINESS OVERVIEW
24.21.2 PRODUCT OFFERINGS
24.22 SHIN-ETSU CHEMICAL
24.22.1 BUSINESS OVERVIEW
24.22.2 PRODUCT OFFERINGS
24.23 SIGACHI INDUSTRIES
24.23.1 BUSINESS OVERVIEW
24.23.2 PRODUCT OFFERINGS
24.24 SPECTRUM CHEMICAL
24.24.1 BUSINESS OVERVIEW
24.24.2 PRODUCT OFFERINGS
24.25 TEREOS
24.25.1 BUSINESS OVERVIEW
24.25.2 PRODUCT OFFERINGS
24.26 THE LUBRIZOL CORPORATION
24.26.1 BUSINESS OVERVIEW
24.26.2 PRODUCT OFFERINGS
24.27 WACKER CHEMIE
24.27.1 BUSINESS OVERVIEW
24.27.2 PRODUCT OFFERINGS

25 REPORT SUMMARY
25.1 KEY TAKEAWAYS
25.2 STRATEGIC RECOMMENDATIONS

26 QUANTITATIVE SUMMARY
26.1 EXCIPIENT
26.1.1 NORTH AMERICA: EXCIPIENT SEGMENTATION
26.1.2 EUROPE: EXCIPIENT SEGMENTATION
26.1.3 APAC: EXCIPIENT SEGMENTATION
26.1.4 LATIN AMERICA: EXCIPIENT SEGMENTATION
26.1.5 MIDDLE EAST & AFRICA: EXCIPIENT SEGMENTATION
26.2 BIOLOGICS
26.2.1 NORTH AMERICA: BIOLOGICS SEGMENTATION
26.2.2 EUROPE: BIOLOGICS SEGMENTATION
26.2.3 APAC: BIOLOGICS SEGMENTATION
26.2.4 LATIN AMERICA: BIOLOGICS SEGMENTATION
26.2.5 MIDDLE EAST & AFRICA: BIOLOGICS SEGMENTATION
26.3 SCALE OF OPERATION
26.3.1 NORTH AMERICA: SCALE OF OPERATION SEGMENTATION
26.3.2 EUROPE: SCALE OF OPERATION SEGMENTATION
26.3.3 APAC: SCALE OF OPERATION SEGMENTATION
26.3.4 LATIN AMERICA: SCALE OF OPERATION SEGMENTATION
26.3.5 MIDDLE EAST & AFRICA: SCALE OF OPERATION SEGMENTATION
26.4 END-USER
26.4.1 NORTH AMERICA: END-USER SEGMENTATION
26.4.2 EUROPE: END-USER SEGMENTATION
26.4.3 APAC: END-USER SEGMENTATION
26.4.4 LATIN AMERICA: END-USER SEGMENTATION
26.4.5 MIDDLE EAST & AFRICA: END-USER SEGMENTATION
26.5 GEOGRAPHY
26.5.1 BULKING AGENTS: GEOGRAPHY SEGMENTATION
26.5.2 SOLUBILIZERS & SURFACTANTS: GEOGRAPHY SEGMENTATION
26.5.3 BUFFERING & TONICITY AGENTS: GEOGRAPHY SEGMENTATION
26.5.4 OTHER EXCIPIENTS: GEOGRAPHY SEGMENTATION
26.5.5 MONOCLONAL ANTIBODIES: GEOGRAPHY SEGMENTATION
26.5.6 VACCINES: GEOGRAPHY SEGMENTATION
26.5.7 OTHER BIOLOGICS: GEOGRAPHY SEGMENTATION
26.5.8 COMMERCIAL: GEOGRAPHY SEGMENTATION
26.5.9 RESEARCH: GEOGRAPHY SEGMENTATION
26.5.10 PHARMA & BIOTECH COMPANIES: GEOGRAPHY SEGMENTATION
26.5.11 CMOS & CDMOS: GEOGRAPHY SEGMENTATION
26.5.12 ACADEMIC & RESEARCH INSTITUTES: GEOGRAPHY SEGMENTATION

27 APPENDIX
27.1 ABBREVIATIONS

LIST OF EXHIBITS

EXHIBIT 1 SEGMENTATION OF GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
EXHIBIT 3 BIOPHARMACEUTICAL CLASSIFICATION SYSTEM OF EXCIPIENTS
EXHIBIT 4 LIST OF EXCIPIENTS INCLUDED IN EACH BCSE CLASS
EXHIBIT 5 SEGMENTATION OF GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET
EXHIBIT 6 IMPACT OF EMERGING DEMAND FOR NOVEL EXCIPIENTS IN DRUG PRODUCT DEVELOPMENT
EXHIBIT 7 US FDA SOUGHT INDUSTRY INPUT ON NOVEL EXCIPIENTS
EXHIBIT 8 IMPACT OF HIGH DEMAND FOR VACCINES AND CELL & GENE THERAPY-BASED EXCIPIENTS
EXHIBIT 9 IMPACT OF EXHAUSTIVE PIPELINE OF BIOLOGICS & BIOSIMILARS
EXHIBIT 10 VACCINES IN PIPELINE FOR VARIOUS INFECTIOUS DISEASES
EXHIBIT 11 DCVMN PIPELINE: NUMBER OF VACCINE DEVELOPMENT PROJECTS (2019)
EXHIBIT 12 BIOSIMILARS IN DEVELOPMENT PHASES (2013 & 2020)
EXHIBIT 13 IMPACT OF GROWING PENETRATION OF BIOPHARMACEUTICAL DRUGS
EXHIBIT 14 AGGREGATE VALUE OF GLOBAL PHARMACEUTICAL INDUSTRY 2015-2020 ($ TRILLION)
EXHIBIT 15 IMPACT OF GROWING PREVALENCE OF CANCER & INFECTIOUS DISEASES
EXHIBIT 16 ESTIMATED NEW CASES OF TOP CANCERS IN 2022 (%)
EXHIBIT 17 REGIONAL PREVALENCE OF LEADING INFECTIOUS DISEASES
EXHIBIT 18 IMPACT OF RISING NUMBER OF PRODUCT APPROVALS FOR BIOLOGICS
EXHIBIT 19 US FDA APPROVALS OF NMES AND BIOLOGICS (2011-2020)
EXHIBIT 20 DEVELOPMENT OF BIOLOGIC MEDICINES BY PRODUCT CATEGORY
EXHIBIT 21 IMPACT OF INCREASING NEED FOR OUTSOURCING BIOPHARMACEUTICAL EXCIPIENT MANUFACTURING
EXHIBIT 22 IMPACT OF EMERGING NEED FOR MULTI-FUNCTIONAL EXCIPIENTS
EXHIBIT 23 IMPACT OF REGULATORY CHALLENGES IN MANUFACTURING BIOPHARMACEUTICAL EXCIPIENTS
EXHIBIT 24 IMPACT OF SUPPLY CHAIN AND INTEGRITY ISSUES WITH BIOPHARMACEUTICAL EXCIPIENTS
EXHIBIT 25 IMPACT OF CHALLENGES OF FORMULATING BIOPHARMACEUTICAL EXCIPIENTS
EXHIBIT 26 SEARCH RESULTS OF MOST COMMONLY OCCURRING EXCIPIENTS
EXHIBIT 27 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021-2027 ($ MILLION)
EXHIBIT 28 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY TYPE
EXHIBIT 29 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS
EXHIBIT 30 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION
EXHIBIT 31 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER
EXHIBIT 32 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY
EXHIBIT 33 FIVE FORCES ANALYSIS 2021
EXHIBIT 34 INCREMENTAL GROWTH BY EXCIPIENT 2021 & 2027
EXHIBIT 35 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT
EXHIBIT 36 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT: INCREMENTAL GROWTH
EXHIBIT 37 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT: ABSOLUTE GROWTH
EXHIBIT 38 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS BULKING AGENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 39 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS BULKING AGENTS MARKET 2021-2027 ($ MILLION)
EXHIBIT 40 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 41 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS SOLUBILIZERS & SURFACTANTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 42 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS SOLUBILIZERS & SURFACTANTS MARKET 2021-2027 ($ MILLION)
EXHIBIT 43 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 44 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS BUFFERING & TONICITY AGENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 45 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS BUFFERING & TONICITY AGENTS MARKET 2021-2027 ($ MILLION)
EXHIBIT 46 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 47 GLOBAL OTHER BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 48 GLOBAL OTHER BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021-2027 ($ MILLION)
EXHIBIT 49 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 50 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
EXHIBIT 51 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS
EXHIBIT 52 DISTRIBUTION OF INACTIVE INGREDIENTS IN BIOLOGIC FORMULATIONS
EXHIBIT 53 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS: INCREMENTAL GROWTH
EXHIBIT 54 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS: ABSOLUTE GROWTH
EXHIBIT 55 GLOBAL MONOCLONAL ANTIBODY EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 56 GLOBAL MONOCLONAL ANTIBODY EXCIPIENTS MARKET 2021-2027 ($ MILLION)
EXHIBIT 57 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 58 GLOBAL VACCINE EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 59 GLOBAL VACCINE EXCIPIENTS MARKET 2021-2027 ($ MILLION)
EXHIBIT 60 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 61 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS OTHER BIOLOGICS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 62 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY OTHER BIOLOGICS 2021-2027 ($ MILLION)
EXHIBIT 63 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 64 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 65 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION
EXHIBIT 66 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION: INCREMENTAL GROWTH
EXHIBIT 67 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION: ABSOLUTE GROWTH
EXHIBIT 68 GLOBAL COMMERCIAL BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 69 GLOBAL COMMERCIAL BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021-2027 ($ MILLION)
EXHIBIT 70 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 71 GLOBAL RESEARCH BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 72 GLOBAL RESEARCH BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021-2027 ($ MILLION)
EXHIBIT 73 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 74 INCREMENTAL GROWTH BY END-USER 2021 & 2027
EXHIBIT 75 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER
EXHIBIT 76 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER: INCREMENTAL GROWTH
EXHIBIT 77 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER: ABSOLUTE GROWTH
EXHIBIT 78 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS PHARMA & BIOTECH COMPANIES MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 79 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS PHARMA & BIOTECH COMPANIES MARKET 2021-2027 ($ MILLION)
EXHIBIT 80 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 81 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS CMOS & CDMOS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 82 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS CMOS & CDMOS MARKET 2021-2027 ($ MILLION)
EXHIBIT 83 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 84 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS ACADEMIC & RESEARCH INSTITUTES MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 85 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS ACADEMIC & RESEARCH INSTITUTES MARKET 2021-2027 ($ MILLION)
EXHIBIT 86 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 87 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 88 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY
EXHIBIT 89 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY: KEY COUNTRIES 2021 ($ MILLION)
EXHIBIT 90 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY: INCREMENTAL GROWTH
EXHIBIT 91 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY: ABSOLUTE GROWTH
EXHIBIT 92 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY COUNTRIES (2021)
EXHIBIT 93 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 94 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021-2027 ($ MILLION)
EXHIBIT 95 INCREMENTAL GROWTH BY EXCIPIENT 2021 & 2027
EXHIBIT 96 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
EXHIBIT 97 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 98 INCREMENTAL GROWTH BY END-USER 2021 & 2027
EXHIBIT 99 INCREMENTAL GROWTH IN NORTH AMERICA 2021 & 2027
EXHIBIT 100 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN US 2021-2027 ($ MILLION)
EXHIBIT 101 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN CANADA 2021-2027 ($ MILLION)
EXHIBIT 102 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY COUNTRIES (2021)
EXHIBIT 103 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 104 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021-2027 ($ MILLION)
EXHIBIT 105 INCREMENTAL GROWTH BY EXCIPIENT 2021 & 2027
EXHIBIT 106 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
EXHIBIT 107 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 108 INCREMENTAL GROWTH BY END-USER 2021 & 2027
EXHIBIT 109 INCREMENTAL GROWTH IN EUROPE 2021 & 2027
EXHIBIT 110 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN GERMANY 2021-2027 ($ MILLION)
EXHIBIT 111 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN FRANCE 2021-2027 ($ MILLION)
EXHIBIT 112 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN THE UK 2021-2027 ($ MILLION)
EXHIBIT 113 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN SWITZERLAND 2021-2027 ($ MILLION)
EXHIBIT 114 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN ITALY 2021-2027 ($ MILLION)
EXHIBIT 115 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN SPAIN 2021-2027 ($ MILLION)
EXHIBIT 116 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY COUNTRIES (2021)
EXHIBIT 117 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 118 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021-2027 ($ MILLION)
EXHIBIT 119 INCREMENTAL GROWTH BY EXCIPIENT 2021 & 2027
EXHIBIT 120 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
EXHIBIT 121 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 122 INCREMENTAL GROWTH BY END-USER 2021 & 2027
EXHIBIT 123 INCREMENTAL GROWTH IN APAC 2021 & 2027
EXHIBIT 124 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN CHINA 2021-2027 ($ MILLION)
EXHIBIT 125 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN JAPAN 2021-2027 ($ MILLION)
EXHIBIT 126 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN SOUTH KOREA 2021-2027 ($ MILLION)
EXHIBIT 127 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN INDIA 2021-2027 ($ MILLION)
EXHIBIT 128 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN AUSTRALIA 2021-2027 ($ MILLION)
EXHIBIT 129 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY COUNTRIES (2021)
EXHIBIT 130 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 131 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021-2027 ($ MILLION)
EXHIBIT 132 INCREMENTAL GROWTH BY EXCIPIENT 2021 & 2027
EXHIBIT 133 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
EXHIBIT 134 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 135 INCREMENTAL GROWTH BY END-USER 2021 & 2027
EXHIBIT 136 INCREMENTAL GROWTH IN LATIN AMERICA 2021 & 2027
EXHIBIT 137 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN BRAZIL 2021-2027 ($ MILLION)
EXHIBIT 138 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN MEXICO 2021-2027 ($ MILLION)
EXHIBIT 139 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN ARGENTINA 2021-2027 ($ MILLION)
EXHIBIT 140 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY COUNTRIES (2021)
EXHIBIT 141 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 142 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021-2027 ($ MILLION)
EXHIBIT 143 INCREMENTAL GROWTH BY EXCIPIENT 2021 & 2027
EXHIBIT 144 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
EXHIBIT 145 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 146 INCREMENTAL GROWTH BY END-USER 2021 & 2027
EXHIBIT 147 INCREMENTAL GROWTH IN THE MIDDLE EAST & AFRICA 2021 & 2027
EXHIBIT 148 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN TURKEY 2021-2027 ($ MILLION)
EXHIBIT 149 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN SAUDI ARABIA 2021-2027 ($ MILLION)
EXHIBIT 150 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN THE UAE 2021-2027 ($ MILLION)
EXHIBIT 151 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN SOUTH AFRICA 2021-2027 ($ MILLION)
EXHIBIT 152 PURE AND DIVERSIFIED PLAYERS IN THE GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET
EXHIBIT 153 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY VENDOR STRENGTHS & CAPABILITY ANALYSIS
EXHIBIT 154 POSITION OF MAJOR PLAYERS IN THE GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET
EXHIBIT 155 MERCK KGAA: TOTAL REVENUE 2019-2021 ($ MILLION)
EXHIBIT 156 MERCK KGAA: REVENUE BY SEGMENT 2019-2021 ($ MILLION)
EXHIBIT 157 MERCK KGAA: TOTAL R&D EXPENDITURE 2019-2021 ($ MILLION)
EXHIBIT 158 MERCK KGAA: REVENUE BY GEOGRAPHY 2019-2021 ($ MILLION)
EXHIBIT 159 BASF: TOTAL REVENUE 2019-2021 ($ MILLION)
EXHIBIT 160 BASF: REVENUE BY SEGMENT 2019-2021 ($ MILLION)
EXHIBIT 161 BASF: TOTAL R&D EXPENDITURE 2019-2021 ($ MILLION)
EXHIBIT 162 BASF: REVENUE BY GEOGRAPHY 2019-2021 ($ MILLION)
EXHIBIT 163 AVANTOR: TOTAL REVENUE 2019-2021 ($ MILLION)
EXHIBIT 164 AVANTOR: REVENUE BY SEGMENT 2019-2021 ($ MILLION)
EXHIBIT 165 AVANTOR: REVENUE BY PRODUCT LINE 2019-2021 ($ MILLION)
EXHIBIT 166 EVONIK INDUSTRIES: TOTAL REVENUE 2019-2021 ($ MILLION)
EXHIBIT 167 EVONIK INDUSTRIES: REVENUE BY SEGMENT 2020-2021 ($ MILLION)
EXHIBIT 168 EVONIK INDUSTRIES: TOTAL R&D EXPENDITURE 2019-2021 ($ MILLION)
EXHIBIT 169 EVONIK INDUSTRIES: REVENUE BY GEOGRAPHY 2019-2021 ($ MILLION)
EXHIBIT 170 ASSOCIATED BRITISH FOODS: TOTAL REVENUE 2019-2021 ($ MILLION)
EXHIBIT 171 ASSOCIATED BRITISH FOODS: REVENUE BY SEGMENT 2019-2021 ($ MILLION)
EXHIBIT 172 ASSOCIATED BRITISH FOODS: TOTAL R&D EXPENDITURE 2019-2021 ($ MILLION)
EXHIBIT 173 ASSOCIATED BRITISH FOODS: REVENUE BY GEOGRAPHY 2019-2021 ($ MILLION)
EXHIBIT 174 MEGGLE: MAJOR PRODUCT OFFERINGS
EXHIBIT 175 PFANSTIEHL: MAJOR PRODUCT OFFERINGS

LIST OF TABLES

TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2015?2021
TABLE 3 EXCIPIENTS USED IN BIOPHARMACEUTICAL FORMULATIONS & THEIR EFFECTS
TABLE 4 CATEGORIES AND EXAMPLES OF SOME BIOPHARMACEUTICAL EXCIPIENTS IN FORMULATING VACCINES
TABLE 5 EXAMPLES OF EXCIPIENTS IN US LICENSED CELL & GENE THERAPY PRODUCTS
TABLE 6 PERCENTAGE SHARE OF VARIOUS BIOPHARMACEUTICALS WITH SMALL MOLECULES 2015 & 2020
TABLE 7 TOTAL REVENUE SHARE OF BIOPHARMACEUTICALS AMONG TOP PHARMACEUTICAL COMPANIES (2012)
TABLE 8 MERCK KGAA: MAJOR PRODUCT OFFERINGS
TABLE 9 BASF: MAJOR PRODUCT OFFERINGS
TABLE 10 AVANTOR: MAJOR PRODUCT OFFERINGS
TABLE 11 EVONIK INDUSTRIES: MAJOR PRODUCT OFFERINGS
TABLE 12 ROQUETTE FRÈRES: MAJOR PRODUCT OFFERINGS
TABLE 13 ASSOCIATED BRITISH FOODS: MAJOR PRODUCT OFFERINGS
TABLE 14 ACETO: MAJOR PRODUCT OFFERINGS
TABLE 15 ANGUS CHEMICAL COMPANY: MAJOR PRODUCT OFFERINGS
TABLE 16 APOTHECON PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS
TABLE 17 ASHLAND: MAJOR PRODUCT OFFERINGS
TABLE 18 BIOSPECTRA: MAJOR PRODUCT OFFERINGS
TABLE 19 BOC SCIENCES: MAJOR PRODUCT OFFERINGS
TABLE 20 CG GROUP: MAJOR PRODUCT OFFERINGS
TABLE 21 CLARIANT: MAJOR PRODUCT OFFERINGS
TABLE 22 COLORCON: MAJOR PRODUCT OFFERINGS
TABLE 23 DFE PHARMA: MAJOR PRODUCT OFFERINGS
TABLE 24 DOW: MAJOR PRODUCT OFFERINGS
TABLE 25 EASTMAN CHEMICAL COMPANY: MAJOR PRODUCT OFFERINGS
TABLE 26 IMCD: MAJOR PRODUCT OFFERINGS
TABLE 27 INNOPHOS: MAJOR PRODUCT OFFERINGS
TABLE 28 INVITRIA: MAJOR PRODUCT OFFERINGS
TABLE 29 JRS PHARMA: MAJOR PRODUCT OFFERINGS
TABLE 30 KIRSCH PHARMA: MAJOR PRODUCT OFFERINGS
TABLE 31 NOVO NORDISK: MAJOR PRODUCT OFFERINGS
TABLE 32 PHARMONIX BIOLOGICALS: MAJOR PRODUCT OFFERINGS
TABLE 33 SHIN-ETSU CHEMICAL: MAJOR PRODUCT OFFERINGS
TABLE 34 SIGACHI INDUSTRIES: MAJOR PRODUCT OFFERINGS
TABLE 35 SPECTRUM CHEMICAL: MAJOR PRODUCT OFFERINGS
TABLE 36 TEREOS: MAJOR PRODUCT OFFERINGS
TABLE 37 THE LUBRIZOL CORPORATION: MAJOR PRODUCT OFFERINGS
TABLE 38 WACKER CHEMIE: MAJOR PRODUCT OFFERINGS
TABLE 39 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021?2027 ($ MILLION)
TABLE 40 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021?2027 (%)
TABLE 41 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021?2027 ($ MILLION)
TABLE 42 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021?2027 (%)
TABLE 43 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021?2027 ($ MILLION)
TABLE 44 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021?2027 (%)
TABLE 45 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021?2027 ($ MILLION)
TABLE 46 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021?2027 (%)
TABLE 47 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021?2027 ($ MILLION)
TABLE 48 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021?2027 (%)
TABLE 49 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021?2027 ($ MILLION)
TABLE 50 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021?2027 (%)
TABLE 51 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021?2027 ($ MILLION)
TABLE 52 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021?2027 (%)
TABLE 53 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021?2027 ($ MILLION)
TABLE 54 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021?2027 (%)
TABLE 55 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021?2027 ($ MILLION)
TABLE 56 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021?2027 (%)
TABLE 57 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021?2027 ($ MILLION)
TABLE 58 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021?2027 (%)
TABLE 59 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021?2027 ($ MILLION)
TABLE 60 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021?2027 (%)
TABLE 61 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021?2027 ($ MILLION)
TABLE 62 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021?2027 (%)
TABLE 63 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021?2027 ($ MILLION)
TABLE 64 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021?2027 (%)
TABLE 65 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021?2027 ($ MILLION)
TABLE 66 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021?2027 (%)
TABLE 67 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021?2027 ($ MILLION)
TABLE 68 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021?2027 (%)
TABLE 69 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021?2027 ($ MILLION)
TABLE 70 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021?2027 (%)
TABLE 71 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021?2027 ($ MILLION)
TABLE 72 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021?2027 (%)
TABLE 73 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021?2027 ($ MILLION)
TABLE 74 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021?2027 (%)
TABLE 75 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021?2027 ($ MILLION)
TABLE 76 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021?2027 (%)
TABLE 77 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021?2027 ($ MILLION)
TABLE 78 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021?2027 (%)
TABLE 79 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021?2027 ($ MILLION)
TABLE 80 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021?2027 (%)
TABLE 81 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021?2027 ($ MILLION)
TABLE 82 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021?2027 (%)
TABLE 83 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021?2027 ($ MILLION)
TABLE 84 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021?2027 (%)
TABLE 85 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021?2027 ($ MILLION)
TABLE 86 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021?2027 (%)
TABLE 87 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY 2021?2027 ($ MILLION)
TABLE 88 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY 2021?2027 (%)
TABLE 89 GLOBAL BIOPHARMACEUTICAL BULKING AGENTS MARKET BY GEOGRAPHY 2021?2027 ($ MILLION)
TABLE 90 GLOBAL BIOPHARMACEUTICAL BULKING AGENTS MARKET BY GEOGRAPHY 2021?2027 (%)
TABLE 91 GLOBAL BIOPHARMACEUTICAL SOLUBILIZERS & SURFACTANTS MARKET BY GEOGRAPHY 2021?2027 ($ MILLION)
TABLE 92 GLOBAL BIOPHARMACEUTICAL SOLUBILIZERS & SURFACTANTS MARKET BY GEOGRAPHY 2021?2027 (%)
TABLE 93 GLOBAL BIOPHARMACEUTICAL BUFFERING & TONICITY AGENTS MARKET BY GEOGRAPHY 2021?2027 ($ MILLION)
TABLE 94 GLOBAL BIOPHARMACEUTICAL BUFFERING & TONICITY AGENTS MARKET BY GEOGRAPHY 2021?2027 (%)
TABLE 95 GLOBAL BIOPHARMACEUTICAL OTHER EXCIPIENTS MARKET BY GEOGRAPHY 2021?2027 ($ MILLION)
TABLE 96 GLOBAL BIOPHARMACEUTICAL OTHER EXCIPIENTS MARKET BY GEOGRAPHY 2021?2027 (%)
TABLE 97 GLOBAL MONOCLONAL ANTIBODY EXCIPIENTS MARKET BY GEOGRAPHY 2021?2027 ($ MILLION)
TABLE 98 GLOBAL MONOCLONAL ANTIBODY EXCIPIENTS MARKET BY GEOGRAPHY 2021?2027 (%)
TABLE 99 GLOBAL VACCINE EXCIPIENTS MARKET BY GEOGRAPHY 2021?2027 ($ MILLION)
TABLE 100 GLOBAL VACCINE EXCIPIENTS MARKET BY GEOGRAPHY 2021?2027 (%)
TABLE 101 GLOBAL OTHER BIOLOGICS MARKET BY GEOGRAPHY 2021?2027 ($ MILLION)
TABLE 102 GLOBAL OTHER BIOLOGICS MARKET BY GEOGRAPHY 2021?2027 (%)
TABLE 103 GLOBAL COMMERCIAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY 2021?2027 ($ MILLION)
TABLE 104 GLOBAL COMMERCIAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY 2021?2027 (%)
TABLE 105 GLOBAL RESEARCH BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY 2021?2027 ($ MILLION)
TABLE 106 GLOBAL RESEARCH BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY 2021?2027 (%)
TABLE 107 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS PHARMA & BIOTECH COMPANIES MARKET BY GEOGRAPHY 2021?2027 ($ MILLION)
TABLE 108 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS PHARMA & BIOTECH COMPANIES MARKET BY GEOGRAPHY 2021?2027 (%)
TABLE 109 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS CMOS & CDMOS MARKET BY GEOGRAPHY 2021?2027 ($ MILLION)
TABLE 110 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS CMOS & CDMOS MARKET BY GEOGRAPHY 2021?2027 (%)
TABLE 111 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS ACADEMIC & RESEARCH INSTITUTES MARKET BY GEOGRAPHY 2021?2027 ($ MILLION)
TABLE 112 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS ACADEMIC & RESEARCH INSTITUTES MARKET BY GEOGRAPHY 2021?2027 (%)

Companies Mentioned

Vendors
• Merck KGAA

Please contact our Customer Support Center to get the complete Table of Contents